Cytokines are involved in intestinal homeostasis and pathological processes associated
with inflammatory bowel disease (IBD). The biological effects of cytokines, including several …

The inflammatory diseases ulcerative colitis and Crohn's disease constitute the two main
forms of inflammatory bowel disease (IBD). They are characterized by chronic, relapsing …

The two major forms of inflammatory bowel disease (IBD), encompassing Crohn's disease
(CD) and ulcerative colitis (UC), are chronic immune-mediated conditions characterised by …

Primary non-response and secondary loss of response remain a significant issue with the
currently available treatment options for a significant proportion of patients with inflammatory …

The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway
constitute the fulcrum in many vital cellular processes, including cell growth, differentiation …

Janus kinase (JAK) inhibitors, also known as jakinibs, are third-generation oral small
molecules that have expanded the therapeutic options for the management of chronic …

In 2018, the pan-Janus kinase (JAK) inhibitor tofacitinib was launched for the treatment of
ulcerative colitis (UC). Although tofacitinib has proven efficacious in patients with active UC …

Introduction: Current available treatments for inflammatory bowel disease (IBD) have some
limitations and new options are needed. Several new molecules are being tested for the …

In recent years, better knowledge of the pathophysiology of inflammatory bowel diseases
(IBD) has led to a relevant expansion of the therapeutic arsenal for these conditions. Janus …

Inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease, are disabling
conditions characterised by chronic, relapsing inflammation of the gastrointestinal tract …